Anne Wojcicki, chief executive officer of genetic testing company 23andMe Inc., has made a comeback. Two years after 23andMe ran afoul of the U.S. Food and Drug Administration for selling tests with health analysis that hadn’t been cleared, her company’s new DNA test is on the market with the reports restored. It’s the first genetic test that’s approved to be sold directly to consumers.
In an interview with Bloomberg TV’s “Studio 1.0” with Emily Chang, Wojcicki spoke about her plans for the company, her attempts to stay normal in the Silicon Valley “bubble” and the embattled neighboring company Theranos Inc.
